1T3 Stock Overview A clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Syndax Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Syndax Pharmaceuticals Historical stock prices Current Share Price US$13.40 52 Week High US$22.20 52 Week Low US$11.90 Beta 0.89 1 Month Change 12.61% 3 Month Change -21.18% 1 Year Change -27.96% 3 Year Change -2.19% 5 Year Change 48.07% Change since IPO -7.38%
Recent News & Updates
Incyte and Syndax Pharmaceuticals Announce U.S. Food and Drug Administration Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes Jan 16
Syndax Pharmaceuticals Announces Additional Positive Data for Revuforj®? (Revumenib) from Augment-101 Trial in Relapsed or Refractory Mnpm1 Aml and Beat Aml Frontline Combination Trial Dec 10
Syndax Pharmaceuticals Presents Positive Revuforj Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting Dec 08
Syndax Pharmaceuticals Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation Nov 16
New minor risk - Share price stability Nov 13
Syndax Pharmaceuticals, Inc. Announces Positive Pivotal Topline Results from Relapsed or Refractory Mnpm1 AML Cohort in Augment-101 Trial of Revumenib Nov 13 See more updates
Incyte and Syndax Pharmaceuticals Announce U.S. Food and Drug Administration Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes Jan 16
Syndax Pharmaceuticals Announces Additional Positive Data for Revuforj®? (Revumenib) from Augment-101 Trial in Relapsed or Refractory Mnpm1 Aml and Beat Aml Frontline Combination Trial Dec 10
Syndax Pharmaceuticals Presents Positive Revuforj Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting Dec 08
Syndax Pharmaceuticals Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation Nov 16
New minor risk - Share price stability Nov 13
Syndax Pharmaceuticals, Inc. Announces Positive Pivotal Topline Results from Relapsed or Refractory Mnpm1 AML Cohort in Augment-101 Trial of Revumenib Nov 13
Syndax Pharmaceuticals, Inc. Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™? (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting Nov 05
Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 29
Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) Aug 15
New minor risk - Share price stability Aug 05
Syndax Announces Pdufa Action Date Extension for Revumenib Nda for Relapsed or Refractory Kmt2ar Acute Leukemia Jul 30
Syndax Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 25 Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index
SSyndax Pharmaceuticals, Inc. Presents Updated Positive Data from BEAT AML and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress Jun 17
Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC Jun 08
Syndax Pharmaceuticals, Inc. Announces Board Changes May 16
Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session Apr 09
Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024 Apr 03
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia Mar 28
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia Mar 27
Syndax Pharmaceuticals, Inc. Announces Executive Changes Mar 19
New minor risk - Profitability Feb 29
Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 21
Now 24% undervalued Dec 20 Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999985 million.
Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting Dec 13
Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease Dec 11
Syndax Pharmaceuticals Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting Nov 03
Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 27
Syndax Pharmaceuticals Announces to Initiate Nda Submission of Revumenib in Relapsed/Refractory Kmt2ar Acute Leukemia Under Fda's Real-Time Oncology Review Program Oct 25
New minor risk - Share price stability Oct 05
Syndax Pharmaceuticals Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stated Interim Analysis Oct 05
Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 26
Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease Jul 25
Syndax Pharmaceuticals, Inc. Announces Executive Changes May 10 Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer Dec 03
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021) Nov 05
Syndax Pharmaceuticals, Inc. Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of Augment-101 Trial of Revumenib in Patients with Acute Leukemias Nov 04
Syndax Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
First half 2022 earnings released Aug 09
Syndax Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Aug 03
Insufficient new directors Aug 02
Investor sentiment improved over the past week Jun 25
Syndax Pharmaceuticals, Inc. Announces Appointment of Keith A. Goldan as Chief Financial Officer Jun 14
Investor sentiment improved over the past week Jun 01
First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.54 loss in 1Q 2021) May 11
Syndax Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022 May 03
Investor sentiment improved over the past week Apr 07
Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022 Mar 31
Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022 Mar 30
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 03
Syndax Pharmaceuticals, Inc. Announces Executive Changes Mar 03
Syndax Pharmaceuticals, Inc. Announces Executive Changes Feb 25
Syndax Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 24 Syndax Pharmaceuticals, Inc. Announces Executive Changes
Syndax Pharmaceuticals, Inc. Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 Dec 15
Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease Dec 12
Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.46 loss in 3Q 2020) Nov 16
Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million. Sep 29
First half 2021 earnings released: US$0.98 loss per share (vs US$0.97 loss in 1H 2020) Aug 11
First quarter 2021 earnings released: US$0.54 loss per share (vs US$0.56 loss in 1Q 2020) May 13
Independent Chairman recently bought €164k worth of stock Apr 24
Full year 2020 earnings released: US$1.87 loss per share (vs US$1.84 loss in FY 2019) Mar 10
Revenue beats expectations Mar 10
Syndax Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 08, 2021 Mar 02
Syndax Pharmaceuticals, Inc. Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD Dec 09
New 90-day high: €19.50 Dec 05
Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting Nov 06
New 90-day high: €16.00 Nov 05
Third quarter 2020 earnings released: US$0.46 loss per share Nov 05
Revenue misses expectations Nov 05
Syndax Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 02, 2020 Oct 28
New 90-day high: €15.30 Oct 19
New 90-day high: €14.50 Sep 17
First half earnings released Aug 07 Syndax Pharmaceuticals, Inc. announced that it has received funding from Frazier Healthcare Partners Jun 30
Shareholder Returns 1T3 DE Biotechs DE Market 7D 2.3% 0.4% 1.9% 1Y -28.0% -6.5% 14.1%
See full shareholder returns
Return vs Market: 1T3 underperformed the German Market which returned 14.1% over the past year.
Price Volatility Is 1T3's price volatile compared to industry and market? 1T3 volatility 1T3 Average Weekly Movement 10.5% Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.0% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 1T3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1T3's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat.
Show more Syndax Pharmaceuticals, Inc. Fundamentals Summary How do Syndax Pharmaceuticals's earnings and revenue compare to its market cap? 1T3 fundamental statistics Market cap €1.17b Earnings (TTM ) -€285.48m Revenue (TTM ) €15.38m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1T3 income statement (TTM ) Revenue US$16.00m Cost of Revenue US$64.19m Gross Profit -US$48.19m Other Expenses US$248.87m Earnings -US$297.06m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.48 Gross Margin -301.21% Net Profit Margin -1,856.64% Debt/Equity Ratio 0%
How did 1T3 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/30 03:27 End of Day Share Price 2025/01/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Syndax Pharmaceuticals, Inc. is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Peter Lawson Barclays Jason Zemansky BofA Global Research Madhu Kumar B. Riley Securities, Inc.
Show 20 more analysts 
